• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At HCA Healthcare’s (HCA) Valuation As Wall Street Highlights Margin Gains And 2026 Growth Plans

    Simply Wall St·01/05/2026 20:14:41
    Listen to the news

    HCA Healthcare (HCA) is back in focus after fresh Wall Street commentary highlighted margin improvements, firm guidance, and disciplined growth plans, prompting investors to reassess the stock’s risk reward profile for 2026.

    See our latest analysis for HCA Healthcare.

    Recent moves in HCA’s share price have been relatively muted, with a 1 day share price return of 0.76% and a 30 day share price return of a 3.35% decline. However, a 1 year total shareholder return of 59.61% and a 5 year total shareholder return of 186.62% point to momentum that has been building over a longer horizon as the company continues to open new emergency rooms and expand facilities like its Florida NICU.

    If this kind of hospital expansion has your attention, it could be a good moment to widen your watchlist with other healthcare stocks that are reshaping care delivery and capacity.

    With HCA shares sitting close to recent analyst targets and the stock already delivering strong multi year returns, the key question now is simple: is there still mispricing here, or is future growth already fully reflected?

    Most Popular Narrative Narrative: 2.4% Undervalued

    With HCA Healthcare closing at $470.39 against a narrative fair value of $481.95, the current setup hinges on how sustainable its earnings drivers really are.

    Upside from state directed and Medicaid supplemental payments is viewed as a key earnings and cash flow driver, reinforcing the case for sustained high single digit revenue and EBITDA growth. Management’s commitment to a 2% to 3% long term volume growth target underpins confidence in organic growth and capacity utilization, supporting a premium relative to hospital peers.

    Read the complete narrative.

    Curious how modest volume targets, policy linked payments, and a lower future earnings multiple still point to upside? The full narrative walks through those moving parts.

    Result: Fair Value of $481.95 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, the story could change quickly if supplemental and Medicaid related payments became less supportive or if policy shifts started to pressure margins and earnings visibility.

    Find out about the key risks to this HCA Healthcare narrative.

    Build Your Own HCA Healthcare Narrative

    If you look at the numbers and reach a different conclusion, or simply prefer to work from your own assumptions, you can build a custom HCA narrative in just a few minutes with Do it your way

    A great starting point for your HCA Healthcare research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.

    Looking for more investment ideas?

    Do not stop with one hospital stock. Broaden your watchlist now with focused screeners that help you spot different types of opportunities before everyone else does.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.